{"id":744962,"date":"2014-06-20T06:30:00","date_gmt":"2014-06-20T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/"},"modified":"2023-03-22T00:04:53","modified_gmt":"2023-03-22T04:04:53","slug":"merck-begins-tender-offer-to-acquire-idenix","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/","title":{"rendered":"Merck Begins Tender Offer to Acquire Idenix"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, is<br \/>\n      commencing today, through a subsidiary, a cash tender offer to purchase<br \/>\n      all outstanding shares of common stock of Idenix Pharmaceuticals, Inc.<br \/>\n      (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire<br \/>\n      Idenix.\n    <\/p>\n<p>\n      Upon the successful closing of the tender offer, stockholders of Idenix<br \/>\n      will receive $24.50 in cash for each share of Idenix common stock<br \/>\n      validly tendered and not validly withdrawn in the offer, without<br \/>\n      interest and less any required withholding taxes. Following the purchase<br \/>\n      of shares in the tender offer, Idenix will become a wholly-owned<br \/>\n      subsidiary of Merck.\n    <\/p>\n<p>\n      Merck will file today with the U.S. Securities and Exchange Commission<br \/>\n      (SEC) a tender offer statement on Schedule TO, which provides the terms<br \/>\n      of the tender offer. Additionally, Idenix will file with the SEC a<br \/>\n      solicitation\/recommendation statement on Schedule 14D-9 that includes<br \/>\n      the recommendation of the Idenix board of directors that Idenix<br \/>\n      stockholders accept the tender offer and tender their shares. As<br \/>\n      previously communicated, the Idenix board of directors has determined<br \/>\n      that the merger agreement and its related transactions, including the<br \/>\n      tender offer, are advisable, fair to and in the best interests of Idenix<br \/>\n      and its stockholders.\n    <\/p>\n<p>\n      The tender offer will expire at 5:00 pm EDT on Monday, Aug. 04, 2014,<br \/>\n      unless extended in accordance with the merger agreement and the<br \/>\n      applicable rules and regulations of the SEC. The closing of the tender<br \/>\n      offer is subject to customary terms and conditions, including the tender<br \/>\n      of a number of shares which, together with shares then owned by Merck<br \/>\n      (if any), represents a majority of the outstanding shares, and the<br \/>\n      expiration or the termination of the waiting period under the<br \/>\n      Hart-Scott-Rodino Antitrust Improvements Act.\n    <\/p>\n<p>\n      MacKenzie Partners, Inc. is acting as information agent for Merck.<br \/>\n      Credit Suisse is serving as financial advisor to Merck with this<br \/>\n      transaction and Hughes Hubbard &#038; Reed LLP as its legal advisor.<br \/>\n      Centerview Partners is serving as financial advisors to Idenix in<br \/>\n      connection with the transactions and Idenix is represented by Sullivan &#038;<br \/>\n      Cromwell.\n    <\/p>\n<p>\n      <b>Additional Information about the Tender Offer<\/b>\n    <\/p>\n<p>\n      This announcement is neither an offer to purchase nor a solicitation of<br \/>\n      an offer to sell shares of Idenix. Merck will file a Tender Offer<br \/>\n      Statement on Schedule TO with the SEC, and Idenix will file a<br \/>\n      Solicitation\/Recommendation Statement on Schedule 14D-9 with respect to<br \/>\n      the offer. Idenix shareholders and other investors are urged to read the<br \/>\n      tender offer materials (including an Offer to Purchase, a related Letter<br \/>\n      of Transmittal and certain other offer documents) and the<br \/>\n      Solicitation\/Recommendation Statement because they contain important<br \/>\n      information, which should be read carefully before any decision is made<br \/>\n      with respect to the tender offer. The Offer to Purchase, the related<br \/>\n      Letter of Transmittal and certain other documents, as well as the<br \/>\n      Solicitation\/Recommendation Statement, will be made available to all<br \/>\n      stockholders of Idenix at no expense to them. The Tender Offer Statement<br \/>\n      and the Solicitation\/Recommendation Statement will also be available at<br \/>\n      no charge on the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50890596&#038;newsitemid=20140620005051&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=1&#038;md5=e005dced361d10514ae18118a9f974af\" rel=\"nofollow\">www.sec.gov<\/a>.<br \/>\n      Free copies of these materials and certain other offering documents will<br \/>\n      be available by mail by contacting Merck at One Merck Drive, Whitehouse<br \/>\n      Station, N.J. 08889.\n    <\/p>\n<p>\n      In addition to the Offer to Purchase, the related Letter of Transmittal<br \/>\n      and certain other offer documents, as well as the<br \/>\n      Solicitation\/Recommendation Statement, Merck and Idenix file annual,<br \/>\n      quarterly and special reports, proxy statements and other information<br \/>\n      with the SEC. You may read and copy any reporters, statements or other<br \/>\n      information filed by Merck or Idenix at the SEC public reference room at<br \/>\n      100 F. Street, N.E., Washington, D.C., 20549. For further information on<br \/>\n      the SEC public reference room, please call 1-800-SEC-0330. Merck\u2019s and<br \/>\n      Idenix\u2019s filings with the SEC are also available to the public from<br \/>\n      commercial document-retrieval services and at the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50890596&#038;newsitemid=20140620005051&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=ae96510985521cff408d3776071f220a\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50890596&#038;newsitemid=20140620005051&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=31c7690418c5e20088f49bae653e6164\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50890596&#038;newsitemid=20140620005051&#038;lan=en-US&#038;anchor=Twitter&#038;index=4&#038;md5=1a0c24efab6f7cb3c5df8e9435ba041c\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50890596&#038;newsitemid=20140620005051&#038;lan=en-US&#038;anchor=Facebook&#038;index=5&#038;md5=26248709fb94c25daa560e6cc904b560\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50890596&#038;newsitemid=20140620005051&#038;lan=en-US&#038;anchor=YouTube&#038;index=6&#038;md5=b0b9b40e472323319c253ba3fe5ce2b4\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Forward looking statements<br \/>\n      include statements regarding the timing and closing of the tender offer<br \/>\n      and the merger transactions, the ability of Merck to complete the<br \/>\n      transactions considering the various closing conditions, and any<br \/>\n      assumptions underlying any of the foregoing. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; the exposure to litigation, including patent<br \/>\n      litigation, and\/or regulatory actions; timing of the tender offer and<br \/>\n      merger; uncertainties as to how many Idenix stockholders will tender<br \/>\n      shares in the tender offer; the possibility that competing offer may be<br \/>\n      made; the possibility that various closing conditions to transactions<br \/>\n      may not be satisfied or waived, including that a governmental entity may<br \/>\n      prohibit, delay or refuse to grant approval for the consummation of the<br \/>\n      transactions; or that a material adverse effect occurs with respect to<br \/>\n      Idenix.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the SEC available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50890596&#038;newsitemid=20140620005051&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=7&#038;md5=9318db8255f9528838924eb519e8f53f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140620005051r2&#038;sid=hq1sf1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Steve Cragle, 908-423-3461<br \/>Investors:<br \/>Joe        Romanelli, 908-423-5185<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix. Upon the successful closing of the tender offer, stockholders of Idenix will receive $24.50 in cash for each share of Idenix common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Idenix will become a wholly-owned subsidiary of Merck. Merck will file today with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, Idenix will file with the SEC a solicitation\/recommendation statement on Schedule 14D-9 that includes the recommendation of the Idenix board of directors that Idenix<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744962","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Begins Tender Offer to Acquire Idenix - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Begins Tender Offer to Acquire Idenix - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix. Upon the successful closing of the tender offer, stockholders of Idenix will receive $24.50 in cash for each share of Idenix common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Idenix will become a wholly-owned subsidiary of Merck. Merck will file today with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, Idenix will file with the SEC a solicitation\/recommendation statement on Schedule 14D-9 that includes the recommendation of the Idenix board of directors that Idenix\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:53+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/\",\"name\":\"Merck Begins Tender Offer to Acquire Idenix - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en\",\"datePublished\":\"2014-06-20T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-idenix\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Begins Tender Offer to Acquire Idenix\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Begins Tender Offer to Acquire Idenix - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/","og_locale":"en_US","og_type":"article","og_title":"Merck Begins Tender Offer to Acquire Idenix - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix. Upon the successful closing of the tender offer, stockholders of Idenix will receive $24.50 in cash for each share of Idenix common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Idenix will become a wholly-owned subsidiary of Merck. Merck will file today with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, Idenix will file with the SEC a solicitation\/recommendation statement on Schedule 14D-9 that includes the recommendation of the Idenix board of directors that Idenix","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:53+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/","name":"Merck Begins Tender Offer to Acquire Idenix - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en","datePublished":"2014-06-20T06:30:00+00:00","dateModified":"2023-03-22T04:04:53+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140620005051r2&sid=hq1sf1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-idenix\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Begins Tender Offer to Acquire Idenix"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"164f3acf-82af-4ec9-8977-9b274ac1a3e4","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744962\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744962"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}